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Plasma retinol-binding protein 4 (RBP4) may be a new
adipokine linked to obesity-induced insulin resistance and
type 2 diabetes. The impact of diabetic nephropathy on
plasma RBP4 levels, however, is not known. We tested the
hypothesis that microalbuminuria is associated with elevated
plasma concentrations of RBP4 in type 2 diabetic subjects.
Retinol, its binding protein and transthyretin (TTR) were
measured in the plasma and urine of 62 type 2 diabetic
subjects, 26 of whom had microalbuminuria. The results were
compared to 35 healthy control subjects. Despite no
differences in plasma retinol, concentrations of the RBP4
were significantly elevated in plasma of diabetic patients and
significantly higher in those with microalbuminuria. The
higher plasma levels of the binding protein in subjects with
microalbuminuria were accompanied by both significantly
elevated plasma TTR and increased urinary levels of RBP4.
There were no correlations of plasma-binding protein levels
and parameters of insulin resistance. Our study suggests that
plasma RBP4 levels in type 2 diabetic patients are affected by
incipient nephropathy. Therefore, further studies evaluating
RBP4 as a regulator of systemic insulin resistance and type 2
diabetes will need to take renal function into consideration.
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Retinol-binding protein 4 (RBP4) was initially recognized as
the primary carrier for vitamin A (retinol) in plasma.1 The
small protein (molecular weight B21 kDa) is synthesized
mainly by the hepatocytes and secreted into plasma bound to
retinol and transthyretin (TTR) as ternary retinol–RBP4–TTR
complex.2 RBP4 expression is also present in extrahepatic
organs including principal insulin-sensitive tissues such as
skeletal muscle and white adipose tissue.3 Recently, it was
shown that RBP4 expression in adipose tissue is upregulated
in a transgenic mouse model with an adipocyte-specific
ablation of the insulin-sensitive GLUT4 resulting in elevated
levels of plasma RBP4.4 It was also reported that RBP4
is elevated in plasma of subjects with obesity, impaired
glucose tolerance and type 2 diabetes mellitus as well as that
elevated RBP4 is associated with parameters of the metabolic
syndrome.5–9 These results suggest that RBP4 may serve
as a potential adipokine playing a role in obesity-induced
insulin resistance and the development of type 2 diabetes
mellitus.10,11
The central importance of RBP4 in the vitamin A
metabolism is reflected in the homeostatic regulation of
plasma retinol, which guarantees a constant and continuous
supply of vitamin A to peripheral tissues.2 Several patho-
physiological conditions, however, might be the cause of
substantial fluctuations of plasma RBP4. Reduced levels
of plasma RBP4 reflect impaired synthesis and/or secretion of
RBP4. This can arise from several hepatopathies, dietary
deficiency of vitamin A or inflammation.12–14 On the other
hand, increased levels of plasma RBP4 have been described in
patients with chronic renal failure, which is attributed to a
reduced glomerular filtration and catabolism of RBP4 in
the kidneys.15,16 Moreover, the impaired catabolism of the
RBP4 complex in the kidneys leads to the accumulation of a
truncated variant of RBP4 in plasma of patients with chronic
renal failure pointing to the central importance of kidney
function in the regulation of plasma RBP4.17
Nephropathy is also a serious microvascular complication
in type 2 diabetic patients.18 The decrease in renal function at
the beginning of diabetic nephropathy is characterized by
slight glomerular dysfunction, which is closely linked to
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elevated urinary albumin excretion in the range of micro-
albuminuria.19 To our knowledge, the impact of nephropathy
on the plasma vitamin A-transport complex and in particular
on RBP4 in type 2 diabetic subjects has not yet been
investigated. This aspect, however, is of specific relevance and
needs to be addressed in the discussion on the importance of
RBP4 as an adipokine and its role in the pathogenesis of
insulin resistance and type 2 diabetes mellitus. We therefore
propose that the presence of incipient nephropathy might
contribute to elevated levels of RBP4 in type 2 diabetic
subjects. For this, we examined the combined effect of both
type 2 diabetes mellitus and the occurrence of microalbumi-
nuria on variables of plasma RBP4 complex as well as their
excretion in urine.
RESULTS
Anthropometric and clinical parameters
Anthropometric and clinical characteristics of type 2 diabetic
patients and controls are shown in Table 1. As expected, body
mass index (BMI), waist circumference, waist-to-hip ratio,
systolic blood pressure and parameters of impaired glucose
utilization, such as fasting glucose, insulin, and homeostasis
model assessment of b-cell function and insulin resistance
(HOMA-IR) score as well as concentrations of interleukin-6
(IL-6) were increased (all Po0.001) in subjects with type 2
diabetes mellitus. Diastolic blood pressure was significantly
higher (Po0.01) in type 2 diabetic patients with micro-
albuminuria. Glycosylated hemoglobin (HbA1c) increased
progressively from normoalbuminuric type 2 diabetic
patients to patients with microalbuminuria (Po0.001). No
differences in the plasma concentrations of cholesterol and
low-density lipoprotein cholesterol were seen between
diabetic groups or controls, whereas concentrations of
high-density lipoprotein (HDL) cholesterol were lower
(Po0.001) in the type 2 diabetic groups. Moreover, type 2
diabetic patients with microalbuminuria had significantly
higher levels of plasma triglycerides (Po0.01) and nonester-
ified fatty acids (NEFA) (Po0.05). Finally, there were no
significant differences in the concentration of plasma
creatinine (P¼ 0.597) and glomerular filtration rate (GFR)
(P¼ 0.658) estimated by the Modification of Diet in Renal
Disease (MDRD) Study Group formula.
Biochemical variables of the RBP4–TTR–complex
There were no significant differences in concentration of
plasma retinol between type 2 diabetic subjects and controls
(Table 2). Concentrations of plasma RBP4, however, were
elevated in normoalbuminuric type 2 diabetic patients
(Po0.05) and were highest in diabetic subjects with
microalbuminuria (Po0.001 microalbuminuric vs controls;
Po0.01 microalbuminuric vs normoalbuminuric). The
higher concentrations of plasma RBP4 were also reflected
by a reduced molar ratio of plasma retinol to plasma RBP4
(Po0.001 microalbuminuric vs controls; Po0.05 micro-
albuminuric vs normoalbuminuric). Furthermore, plasma
TTR was also elevated in microalbuminuric type 2 diabetic
subjects as opposed to normoalbuminuric type 2 diabetic
patients (Po0.05). We also tested whether the higher
concentration of RBP4 in plasma of type 2 diabetic patients
reflected a higher synthesis of RBP4 by adipose tissue or if it
paralleled incipient diabetic nephropathy as measured by
microalbuminuria. To clarify this, we investigated all subjects
Table 1 | Clinical and biochemical characteristics of type 2 diabetic patients and controls
Type 2 diabetic subjects
Controls (n=35) Normoalbuminuria (n=36) Microalbuminuria (n=26)
Age (years) 49 (21–71)a 62 (37–76)b 63 (40–78)b
Sex (M/F) 14/21 18/18 12/14
BMI (kg/m2) 26.2 (19.1–41.5)a 31.5 (22.3–49.3)b 32.0 (22.8–56.9)b
Waist circumference (cm) 89 (64–128)a 105 (82–147)b 102 (88–149)b
WHR 0.86 (0.65–1.21)a 0.93 (0.79–1.15)b 0.94 (0.80–1.07)b
SBP (mm Hg) 122 (88–160)a 138 (102–178)b 133 (109–184)b
DBP (mm Hg) 75 (61–100)a 80 (63–98)a,b 83 (64–108)b
Glucose (mmol/l) 4.91 (4.01–5.53)a 6.27 (2.66–9.87)b 6.43 (4.68–10.5)b
Insulin (mU/l) 5.43 (0.39–21.0) 11.4 (2.96–63.5)b 8.50 (0.89–27.3)b
HbA1c (%) 5.1 (4.2–5.7)a 5.8 (4.6–8.3)b 6.3 (5.5–10.3)c
IL-6 (pg/ml) 1.10 (0.59–3.78)a 2.68 (0.74–7.18)b 2.56 (1.05–25.2)b
HOMA-IR 1.08 (0.10–4.39)a 3.12 (0.74–21.3)b 2.70 (0.25–7.78)b
Cholesterol (mmol/l) 5.68 (3.46–6.66)a,b 5.19 (3.25–7.27)a 6.06 (2.44–8.23)b
LDL cholesterol (mmol/l) 3.45 (1.69–4.79) 3.22 (1.61–4.64) 3.70 (0.99–5.94)
HDL cholesterol (mmol/l) 1.53 (1.02–2.62)a 1.21 (0.59–2.29)b 1.23 (0.76–1.91)b
Triglycerides (mmol/l) 1.04 (0.43–2.64)a 1.31 (0.52–2.92)b 1.65 (0.80–4.24)
NEFA (mmol/l) 0.50 (0.10–1.44)a 0.60 (0.11–1.19)a 0.77 (0.35–1.70)b
Creatinine (mmol/l) 77.8 (63.2–103) 78.9 (51.0–103) 79.2 (54.2–125)
Creatinine clearance (ml/min per 1.73 m2) 83.7 (58.5–101) 84.9 (62.0–112) 83.7 (42.6–141)
Urinary albumin (mg/l) 0 (0–19.9)a 0 (0–27.2)b 61.4 (32.1–449)c
BMI, body mass index; DBP, diastolic blood pressure; F, female; HbA1c, glycosylated hemoglobin; HDL, high-density lipoproteins; HOMA-IR, homeostasis model assessment of
b-cell function and insulin resistance; LDL, low-density lipoproteins; M, male; NEFA, nonesterified fatty acids; SBP, systolic blood pressure; WHR, waist-to-hip ratio.
Data are expressed as median (range).
a,b,cValues with different superscripts in the same line are significantly different.
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with a BMI 425.0 with respect to their concentration of
plasma RBP4 (Figure 1). Although there were indeed no
significant differences for BMI and waist-to-hip ratio
between the groups (data not shown), type 2 diabetic
patients with microalbuminuria did have significantly
elevated levels of plasma RBP4 as compared with normoal-
buminuric type 2 diabetic subjects (P¼ 0.032) and controls
(P¼ 0.002). However, under these conditions, the concentra-
tions of plasma RBP4 did not differ between normoalbumi-
nuric type 2 diabetic subjects and controls (P¼ 0.211).
In consideration of the effects of age, gender, BMI,
microalbuminuria, and type 2 diabetes mellitus on para-
meters of the retinol-transport complex, we calculated a
multivariate linear regression model aiming to predict levels
of plasma RBP4. Using the presence of type 2 diabetes
mellitus and presence of microalbuminuria within one model
left microalbuminuria being significantly associated with
plasma RBP4 (P¼ 0.002), whereas the presence of type 2
diabetes mellitus was no more associated (Table 3). Para-
doxically, the higher concentrations of plasma RBP4 in
microalbuminuric patients were accompanied by an in-
creased excretion of RBP4 in urine (Po0.05). We also
assessed the presence of truncated molecular variants of
plasma RBP4 by surface-enhanced laser desorption/ioniza-
tion time-of-flight mass spectrometry analysis (Table 2).
Mass differences of plasma RBP4 were lower (B19 Da) in
type 2 diabetic patients with microalbuminuria as compared
with controls (Po0.01), but not with type 2 diabetic patients
with normoalbuminuria.
Correlations among variables of the RRP4-transport complex
and diabetic risk factors
The variables of the plasma RBP4-transport complex, retinol,
RBP4 and TTR, were significantly and positively correlated
with each other (data not shown). As depicted in Table 4,
plasma retinol was negatively correlated with IL-6 and
positively correlated with plasma triglycerides (both
Po0.05). Plasma RBP4 had a positive correlation with
waist-to-hip ratio, fasting glucose, HbA1c, plasma triglycer-
ides, NEFA (all Po0.001), waist circumference (Po0.01),
systolic blood pressure, diastolic blood pressure, and urinary
albumin (all Po0.05), but not with BMI, fasting insulin,
HOMA-IR, IL-6, and HDL cholesterol levels. The best
Table 2 | Biochemical variables of the RBP4–TTR complex in plasma and urine of type 2 diabetic patients and controls
Type 2 diabetic subjects
Controls (n=35) Normoalbuminuria (n=36) Microalbuminuria (n=26)
Plasma-Retinol (mmol/l) 1.81 (1.15–2.68) 1.70 (0.40–2.40) 1.74 (1.09–3.02)
Plasma RBP4 (mmol/l) 1.59 (0.88–2.91)a 1.75 (0.90–3.01)b 2.22 (1.41–3.65)c
Retinol/RBP4 indexa 1.17 (0.75–1.83)a 0.95 (0.25–1.64)b 0.81 (0.40 –1.15)c
Plasma TTR (mmol/l) 4.02 (1.68–9.06) 4.22 (1.55–7.83)a 5.20 (2.15–11.0)b
Plasma RBP4 (Da) 21 072 (21 017–21 088)a 21 064 (20 999–21 081)a,b 21 053 (20 970–21 079)b
Urinary RBP4 (nmol/l) 2.43 (0.94–6.43)a 2.56 (1.19–11.8)a 3.60 (1.65–25.3)b
RBP4, retinol-binding protein 4; TTR, transthyretin.
Data are expressed as median (range).
aThe retinol/RBP4 index is the molar ratio of plasma retinol to plasma RBP4.


























Figure 1 | RBP4 levels in plasma of controls (n¼ 20), subjects with
type 2 diabetes mellitus (T2DM) and normoalbuminuria (n¼ 32),
and subjects with T2DM and microalbuminuria (n¼ 23) adjusted
for BMI (425 kg/m2). Plasma RBP4 was elevated in T2DM subjects
with microalbuminuria compared to T2DM subjects with
normoalbuminuria and controls (Mann–Whitney U-rank test). Scatter
plot and bars show individual and median values, respectively.
Table 3 | Linear regression analysis using plasma RBP4 as the
dependent variable and including age, gender, BMI, and
presence of type 2 diabetes (A) or age, gender, BMI,






b 100 (%) P-value
(A)
Age 0.301 0.187 5.6 0.09
Gender 0.14 0.109 1.5 0.27
BMI 0.151 0.086 1.2 0.41
Type 2 diabetes 0.343 0.216 7.5 0.065
Total 15.8
(B)
Age 0.303 0.118 3.6 0.272
Gender 0.154 0.117 1.8 0.218
BMI 0.145 0.017 0.2 0.871
Microalbuminuria 0.443 0.373 16.5 0.002
Total 22.1
BMI, body mass index; RBP4, retinol-binding protein 4.
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variable correlated with diabetic risk factors was the
calculated retinol/RBP4 index, which reflects the saturation
of RBP4 with retinol. The retinol/RBP4 index was signifi-
cantly negatively correlated to BMI, waist circumference,
waist-to-hip ratio, systolic blood pressure, diastolic blood
pressure, fasting glucose, insulin, HbA1c, IL-6, HOMA-IR,
plasma triglycerides, NEFA, and urinary albumin (all
Po0.01) and positively correlated with HDL cholesterol
(Po0.001). Finally, urinary RBP4 excretion showed signifi-
cantly positive correlation with urinary albumin excretion
(Po0.05) and plasma triglycerides (Po0.05). Significant
correlations between plasma TTR and any diabetic risk factor
were not evident.
DISCUSSION
The levels of retinol, RBP4, and TTR in plasma are generally
under homeostatic control.2 However, it is also known that
specific pathophysiological conditions such as vitamin A
deficiency or inflammation are causing depressed levels of
RBP4.13 On the other hand, elevated levels of RBP4 can be
observed in plasma of dialysis patients, even though they
excrete RBP4 in urine.15,16 Because in patients with type 2
diabetes mellitus both situations, an increased inflammatory
status as well as an impairment of kidney function can
exist,19,20 we investigated in this study, whether the presence
of microalbuminuria as an early marker of diabetic nephro-
pathy is associated with changes in the concentrations of
plasma RBP4 and also aimed to verify the hypothesis that
high concentrations of plasma RBP4 are correlated with
parameters of insulin resistance in type 2 diabetic patients.
Our results showed that the higher concentrations of RBP4 in
plasma of type 2 diabetic patients are not only linked to
obesity, but might also be a consequence of incipient diabetic
nephropathy as measured by microalbuminuria. Moreover,
the linear regression model confirmed that the presence of
microalbuminuria, but not type 2 diabetes mellitus alone was
a significant contributor of elevated plasma RBP4. The
findings also suggest that the role of RBP4 in systemic insulin
action needs to be addressed through consideration of RBP4
as a primary regulator of plasma retinol homeostasis.
Keeping this in mind, it is important to note that some
organs other than adipose tissue are important sites of RBP4
synthesis and secretion.21 In particular, there is compelling
evidence showing that the kidneys play an important role in
maintenance of whole-body retinol homeostasis,22,23 which is
regulated by glomerular filtration and subsequent reabsorp-
tion of RBP4 into the proximal tubular cells.24,25 Thus, an
impairment of the GFR results in an accumulation of RBP4
and other low-molecular weight proteins in the plasma.12,26
In the study, although clearance measurements were not
performed, the estimated GFR based on the MDRD Study
Group formula was not different between the groups
indicating that the presence of microalbuminuria was not
related to changes in the GFR. Because the renal clearance of
low-molecular weight proteins is close to the GFR,27 it is
therefore unlikely that changes in the GFR are responsible for
the elevated RBP4 levels. Nevertheless, the lower molar ratios
of retinol to RBP4 in plasma of type 2 diabetic subjects,
which were lowest in patients with microalbuminuria,
indicate the higher percentage of circulating apo-RBP4. This
might be the result of a decreased renal uptake and
catabolism of apo-RBP4 through a damaging effect of filtered
protein on the proximal tubules.28 Because apo-RBP4 has
been considered as a physiological positive-feedback signal
from peripheral tissues for the hepatic release of the RBP4
complex,29 increased apo-RBP4 seems to be a plausible
mechanism whereby RBP4 elevates in plasma of type 2
diabetic subjects with miocroalbuminuria. Further studies
have to clarify if such a renal–hepatic pathway actually exists
and if it is modulated in type 2 diabetic patients and whether
the increased levels of apo-RBP4 stimulate the release of
retinol–RBP4 complex from the liver or extrahepatic tissues.
In plasma, RBP4 is not only present as holo- (retinol-
bound) and apo- (retinol-unbound) form, but also in
different molecular variants, which can be detected by mass
spectrometric analysis. Besides full-length RBP4, one parti-
Table 4 | Significant Spearman rank correlations among variables of the retinol-RBP4-TTR-complex and diabetic risk factors.
Retinol RBP4 Retinol/RBP4 index TTR Urinary RBP4
BMI — — 0.352** — —
Waist circumference — 0.340 4.449 — —
WHR — 0.329*** 0.283** — —
SBP — 0.249* 0.354** — —
DBP — 0.216* 0.314** — —
Glucose — 0.330*** 0.493** — —
Insulin — — 0.413** — —
HbA1c — 0.420*** 0.615** — —
IL-6 0.229* — 0.474** — —
HOMA-IR — — 0.458** — —
HDL cholesterol — — 0.381*** — —
Triglycerides 0.222* 0.453*** 0.345** — 0.239*
NEFA — 0.356*** 0.315** — —
Urinary albumin — 0.197* 0.288** — 0.260*
BMI, body mass index; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP diastolic blood pressure; HbA1c, glycosylated hemoglobin; NEFA, non esterified fatty acids;
LDL, low density lipoproteins; HDL, high density lipoproteins; HOMA-IR, Homeostasis model assessment of b-cell function and insulin resistance.
*Po0.05; **Po0.01; ***Po0.001.
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cular RBP4 variant differing by the loss of one C-terminal
leucine residue can be detected in normal plasma.30,31 In
plasma from patients with chronic renal failure, however, a
truncated RBP4 variant with two C-terminal leucine losses is
strongly evident,30 a fact which prompted us to determine
molecular masses of plasma RBP4 in type 2 diabetic patients
using surface-enhanced laser desorption/ionization time-of-
flight mass spectrometry. A significant difference in mole-
cular masses of RBP4 between controls and type 2 diabetic
patients with microalbuminuria was observed. However, the
difference of about 19 Da is not indicative for the terminal
loss of an amino-acid residue and suggests rather a rapid
clearance of truncated RBP4 by the kidneys of type 2 diabetic
patients. The cause of this mass difference is unknown and
needs further investigation.
This study also considered the association between
elevated RBP4, type 2 diabetes, and the inflammatory
response. Because inflammation is thought to suppress the
hepatic RBP4 mRNA synthesis,32,33 plasma concentrations of
both RBP4 and retinol decreased as a result of the
inflammatory reaction.13,14 Therefore, it is necessary to
consider the inflammatory status of the subjects by measur-
ing plasma IL-6, the main stimulator of acute-phase
response.34 Although in the study type 2 diabetic subjects
had elevated concentrations of IL-6 in plasma, differences in
plasma retinol were not evident suggesting that type 2
diabetes mellitus is a condition in which high concentrations
of IL-6 are not associated with a decrease of plasma retinol.
Interestingly, the higher IL-6 levels in subjects with type 2
diabetes mellitus were associated by increased levels of RBP4
in plasma, which is contradictory to the hypothesis of an
inflammation-induced suppression of RBP4 synthesis by the
liver.32,33 It remains to be seen whether this paradoxical
observation in the plasma retinol transport is attributed to so
far unknown mechanisms in the obesity-induced inflamma-
tory signaling pathways of type 2 diabetic subjects.
Although several studies have shown that RBP4 is indeed a
secretion product of white adipose tissue,3,4,21,35 further
research is required to investigate whether RBP4 is causally
involved in the pathogenesis of obesity and type 2 diabetes
mellitus, and if so, determine whether RBP4-target therapies
would be effective. One therapeutic agent that has been
suggested is 4-(N-hydroxyphenyl) retinamide (fenretinide), a
synthetic retinoid designed for cancer therapy. Fenretinide
application in a mouse model has improved glucose tolerance
and insulin sensitivity by lowering plasma RBP4, presumably
through stimulation of RBP4 excretion in the kidney.4 Our
results, however, demonstrate that despite a higher excretion
of RBP4 in urine, levels of RBP4 were elevated in plasma of
type 2 diabetic subjects, a situation that was also reported by
other investigators.7 It remains therefore to be scrutinized
whether fenretinide-induced urinary RBP4 excretion is
feasible to reduce RBP4 in plasma of diabetic subjects also
with regard to reported side effects of the retinol-transport
system.36 In addition, urinary excretion of RBP4 has long
been recommended as a useful marker for the detection of
minor changes in proximal tubular function long before the
occurrence of elevation in other markers such as overt
proteinuria or a rise in plasma creatinine.37 RBP4 excretion is
also associated with the excretion of other marker proteins of
tubular proteinuria, such as albumin, b2-microglobulin, or
N-acetyl-b-D-glucosamidase.38–40 Thereby, the severity of
proteinuria is correlated with the decreased uptake of low-
molecular weight proteins in the proximal tubule.28 The
positive correlation of urinary RBP4 with urinary albumin
therefore corroborates that an increase in the filtered load of
albumin may be responsible for increased urinary excretion
of RBP4 by competition for the reabsorption sites in the
proximal tubulus.41 The results also implicate that incipient
nephropathy in type 2 diabetic patients may be a renal
disorder consisting of a tubulopathy as well as a glomerulo-
pathy occurring simultaneously.
Although the sample size in this study was small, plasma
RBP4 showed significant correlations with diabetic risk
factors, such as waist circumference, systolic blood pressure,
diastolic blood pressure, fasting plasma glucose, HbA1c,
plasma triglycerides, and NEFA. We were, however, not able
to find any significant correlation between plasma RBP4 and
parameters of insulin resistance such as plasma insulin or
HOMA-IR score. This is contrary to results of recently
published studies.4,8,9 Because the calculated molar ratio of
retinol to RBP4 correlated negatively with almost all
investigated diabetic risk factors, it is indicative that rather
than holo-RBP4 itself, the actual amount of apo-RBP4 seems
to play a crucial role in mediating RBP4-related effects on
glucose metabolism. This suggestion, however, should be
proven by further studies.
In conclusion, our results show that despite the presence
of inflammation and increased renal excretion of RBP4,
concentrations of RBP4 in plasma of obese type 2 diabetic
patients were increased and were related to the presence of
incipient nephropathy indicated by microalbuminuria. We
therefore suggest that diabetic nephropathy is an additional
factor that has to be considered in the discussion of RBP4 as




A total of 62 adult patients with type 2 diabetes mellitus (American
Diabetes Association criteria) were recruited from the MESY-BEPO
cohort, which has been established by the Department of
Endocrinology, Diabetes and Nutrition, Charite´-University Medi-
cine Berlin, Germany. The group consisted of 30 men and
32 women, aged between 37 and 78 years (median 63 years). They
were divided according to urinary albumin excretion into two
groups: 36 with normal urinary albumin excretion (o30 mg/l) and
26 with microalbuminuria (430 mg/l). Diabetic patients were
compared with 35 healthy subjects (14 men and 21 women), aged
between 21 and 71 years (median age of 49 years). Blood was
sampled after an overnight fast into EDTA tubes and centrifuged for
plasma preparation. The subjects also provided a concurrent
morning daytime specimen of urine. Aliquots of both, plasma and
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urine were stored at 801C until assayed. The study was approved
by the Institutional Review Board, and an informed consent was
obtained before the study from each subject.
Measurement of laboratory parameters
Anthropometry was performed as described previously.20 Plasma
samples were analyzed for glucose, insulin, cholesterol, low-density
lipoprotein and HDL cholesterol, triglycerides and creatinine with a
Cobas Mira Analyzer (Roche, Mannheim, Germany). The intra-
assay coefficent of variation was: glucose 5.5%; insulin 6%;
cholesterol 5.1%; HDL cholesterol 5.4%; and triglycerides 5.1%.
Plasma NEFA was quantified using a colorimetric assay (NEFA,
Wako, Neuss, Germany). Inter-assay coefficent of variation was
4.7%. IL-6 was determined by ELISA and HbA1c by high-
performance liquid chromatography as described.20 Urinary albu-
min was measured by immunological methods (ABX Diagnostics,
Zurich, Switzerland) according to the manufacturer’s instructions.
Analytical determination of plasma retinol, RBP4, and TTR
Concentrations of plasma retinol were measured using a modified
gradient reversed-phase high-performance liquid chromatography-
system (Waters, Eschborn, Germany) after organic extraction. For
separation of the compounds, a reversed-phase C30 column (5 mm,
250 4.6 mm; YMC, Wilmington, USA) in line with a C18 pre-
column (Luna, Phenomenex, Germany) was applied as described
previously.42 Retinol was quantified by measuring the absorption at
325 nm using an external retinol standard purchased from Sigma
(Deisenhofen, Germany). The detection limit for retinol was 2.0 ng.
Coefficient of variability over time using control plasma was o4%
for retinol.
Concentrations of RBP4 in plasma and urine were quantitatively
determined by ELISA as described previously.43 Plasma TTR was
measured by use of an ELISA technique adapted from the RBP4
procedure. In detail, wells of microtiter plates were coated by the
addition of rabbit anti-human TTR IgG (DakoCytomation,
Hamburg, Germany) diluted 1:2 000 in 50 ml of 50 mM carbonate
buffer (pH 9.6), incubated for 1 h at 371C, and stored at 41C
overnight. Plates were then washed four times with phosphate-
buffered saline (PBS)-Tween (pH 7.4). For analysis, nonspecific
binding was blocked by the addition of 0.5% bovine serum
albumin diluted in PBS and incubated for 1 h at 371C. After four
additional washings, 50 ml of TTR standard (N Protein Standard/
Standard SL OQIM 13, Dade Behring GmbH, Marburg,
Germany), blank or plasma sample diluted with PBS (pH 7.4)
containing 0.05% bovine serum albumin was placed in triplicate
wells and incubated for 2 h at 371C with constant shaking. After
rinsing the wells four times with PBS-Tween (pH 7.4), 50 ml of
peroxidase-conjugated sheep anti-human TTR IgG (Biotrend,
Cologne, Germany), diluted 1:2 000 in PBS-Tween with 0.05%
bovine serum albumin) was added to each well, and plates were
further incubated for 1 h at 371C. After four final washings, color
was developed by the addition of o-phenylenediamine dihydrochlor-
ide solution (Sigma) and incubated for 20 minutes at 251C.
o-Phenylenediamine dihydrochloride solution (100 ml/well) con-
sisted of 3.7 mM solution in 50 mM disodium phosphate–25 mM
citric acid buffer (pH 5.2) containing 0.012% H2O2. The reaction
was stopped through the addition of 1 M H2SO4 (50ml/well), and
absorbance was measured at 490 nm by use of a spectrophotometer
(Microplate Reader, Bio-Rad, Munich, Germany). The inter-assay
coefficient of variation was 8.1%.
Analysis of molecular variants of RBP4 by mass spectrometry
Molecular variants of RBP4 from plasma were assessed by surface-
enhanced laser desorption/ionization time-of-flight mass spectro-
metry after initial isolation by sequential immunoprecipitation.
Aliquots of 10 ml of plasma was mixed with 5 ml of anti-human RBP4
antibody (DakoCytomation) and incubated for 1 h at 251C. The
mixture was then spiked with 10 ml of Sephadex G-15 (1 mg/ml;
Pharmacia, Uppsala, Sweden) to enhance the precipitation,
vortexed, and incubated for 30 min at 251C. After centrifugation
(16 000 g) for 20 min, the supernatant was removed. The pellet
was then washed three times with 50 ml of PBS (pH 7.4), vortexed,
and centrifuged (16 000 g) for 10 min. The supernatants were
discarded and the remaining pellet was resuspended in 10ml of high-
performance liquid chromatography-grade H2O. For surface
enhanced laser desorption/ionization time-of-flight mass spectro-
metry application, 1ml of the dissolved pellet was deposited onto a
spot of an aluminum ProteinChip array (Ciphergen Biosystems,
Fremont, CA, USA). Finally, 1 ml of a saturated energy-absorbing
molecule solution (EAM sinapinic acid; Ciphergen) dissolved in
50% acetonitrile and 0.5% trifluoroacetic acid was applied to the
spot surface and the sample was allowed to dry. Mass analysis was
performed in a ProteinChip Reader (PBS-II; Ciphergen) as
described in detail elsewhere.44
Data analysis
Results were expressed as medians and ranges. HOMA-IR was
calculated as fasting insulin (mU/l) fasting glucose (mmol/l)/22.5.45
The abbreviated MDRD Study Group formula was used to estimate
the GFR based on age, sex, and serum creatinine (all patients were
Caucasian): MDRD¼ 186.3 (serum creatinine (mg/dl))1.154
(age)0.203 (0.742 if female) mlmin1 per 1.73 m2.46 Statistical
analysis was accomplished by use of nonparametric procedure (SPSS
statistical package, version 12.0, SPSS Inc., Chicago, IL, USA). The
Kruskal–Wallis test was used to test for significant differences in
continuous variables between the groups. If there was a significant
effect, Mann–Whitney U-rank test was performed to describe
differences in proportions between case and control subjects. To
identify independent determinants of plasma RBP4 levels, linear
regression analysis was performed. Potential effects of diabetes or
diabetic nephropathy were investigated after adjustment for age,
gender, and BMI as potential confounders. Spearman rank correlation
coefficients were used to test the association between anthropometric
as well as laboratory parameters and variables of RBP4 transport
complex. Values of Po0.05 were considered significant.
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